ALGS Q3 2022 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+167.1% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$19M-461.5% margin

Net Income

-$19M-453.5% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$164M

Total Liabilities

$42M

Stockholders' Equity

$122M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+167.1%
Gross Profit	$4M	$2M	+167.1%
Operating Income	-$19M	-$33M	+42.7%
Net Income	-$19M	-$33M	+43.8%